$595m octreotide deal grabs Roche


Swiss drugmaker Roche has struck a $595 million (£390 million) deal with US firm Chiasma for Octreolin (octreotide) tablets for treating acromegaly, a rare condition that causes excessive growth.

The active compound, octreotide, is already commercially available as an injection, marketed by Novartis under the name Sandostatin. The tablets are currently in Phase III trials against acromegaly, which is caused by the pituitary gland producing too much growth hormone. The two companies will subsequently look to commercialise the drug for the treatment of neuroendocrine tumours.

Roche will pay $65 million for worldwide marketing rights to the brand and make further payments of up to $530 million as milestones are passed.

Chiasma specialises in turning injectable drug formulations into viable oral equivalents.


Related Content

From molecules to medicines

9 April 2013 Premium contentFeature

news image

Turning an active drug molecule into a finished product requires a lot of chemistry, as Phillip Broadwith discovers

Business roundup

26 October 2011 Business

news image

Industry news, November 2011

Most Read

Schott's glass

29 April 2015 Classic Kit

news image

Life through a lens

First pictures of hydrogen bonds unveiled

26 September 2013 Research

news image

Observation of intermolecular interactions in quinolines could help to settle the nature of this kind of bonding

Most Commented

An unfortunate oversight

27 April 2015 Critical Point

news image

The US Toxic Substances Control Act is in dire need of reform. That demands compromises, says Mark Peplow

Bees 'prefer' neonicotinoid-laced nectar

22 April 2015 Research

news image

Studies debunk the notion that wild bees avoid feeding from pesticide-treated plants